BEIGENE (06160) has seen stronger-than-expected sales growth of its Zanubrutinib in the US and European markets, prompting Haitong International to raise its revenue forecasts for 2025–2027 to $5.3 billion, $6.4 billion, and $7.1 billion, respectively, reflecting a compound annual growth rate of 23%. The firm also revised upward its net profit attributable to shareholders to $360 million, $660 million, and $1.05 billion for the same period, citing better-than-anticipated control over sales and R&D expenses.

Using a weighted average cost of capital (WACC) of 9% and a perpetual growth rate of 4%, Haitong International derived a target price of HK$213.1 for BEIGENE and reiterated its "Outperform" rating.